ScholarIQanswers from OpenAlex & ORCID
Douglas Yee
ResearcherPublications, citations & collaboration network
Douglas Yee is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Douglas Yee have?
ScholarIQindexed works
Douglas Yee has 582 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Douglas Yee have?
ScholarIQcitation count
Douglas Yee has 26,189 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Douglas Yee?
ScholarIQh-index
Douglas Yee has an h-index of 83 in OpenAlex.
What is the i10-index of Douglas Yee?
ScholarIQi10-index
Douglas Yee has an i10-index of 244 in OpenAlex.
What is the ORCID of Douglas Yee?
ScholarIQorcid
The ORCID for Douglas Yee is on the source record.
What is the OpenAlex record for Douglas Yee?
ScholarIQopenalex
The OpenAlex for Douglas Yee is on the source record.
What are the most-cited papers on Douglas Yee?
ScholarIQmost cited works
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Nora Jaskowiak, Anthony Elias, Claudine Isaacs, Kathleen Kemmer, Teresa Helsten, Melanie Majure, Erica Stringer-Reasor, Catherine Parker, Marie Catherine Lee, Tufia C. Haddad, Ronald Cohen, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam L. Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Richard B. Schwab, W. Fraser Symmans, Laura van ‘t Veer, Douglas Yee, Angela DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Donald A. Berry, Laura J. Esserman
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele, Christina Yau, Laura van ‘t Veer, Meredith Buxton, Michael Hogarth, Nola M. Hylton, Melissa Paoloni, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, A. Jo Chien, Anne M. Wallace, Henry G. Kaplan, Judy C. Boughey, Tufia C. Haddad, Kathy S. Albain, Minetta C. Liu, Claudine Isaacs, Qamar J. Khan, Julie E. Lang, Rebecca K. Viscusi, Lajos Pusztai, Stacy L. Moulder, Jane Yuet Ching Hui, Kathleen Kemmer, Anthony Elias, Kirsten K. Edmiston, David Euhus, Barbara Haley, Rita Nanda, Donald W. Northfelt, Debasish Tripathy, William C. Wood, Cheryl A. Ewing, Richard B. Schwab, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Donald A. Berry, Laura J. Esserman
Adaptive Randomization of Neratinib in Early Breast Cancer
John W. Park, Minetta C. Liu, Douglas Yee, Christina Yau, Laura van ‘t Veer, W. Fraser Symmans, Melissa Paoloni, Jane Perlmutter, Nola M. Hylton, Michael Hogarth, Angela DeMichele, Meredith Buxton, A. Jo Chien, Anne M. Wallace, Judy C. Boughey, Tufia C. Haddad, Jane Yuet Ching Hui, Kathleen Kemmer, Henry G. Kaplan, Claudine Isaacs, Rita Nanda, Debasish Tripathy, Kathy S. Albain, Kirsten K. Edmiston, Anthony Elias, Donald W. Northfelt, Lajos Pusztai, Stacy L. Moulder, Julie E. Lang, Rebecca K. Viscusi, David Euhus, Barbara Haley, Qamar J. Khan, William C. Wood, Michelle Melisko, Richard B. Schwab, Teresa Helsten, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Laura J. Esserman, Donald A. Berry
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor, Judy C. Boughey, A. Jo Chien, Anthony Elias, Heather Beckwith, Rita Nanda, Kathy S. Albain, Amy S. Clark, Kathleen Kemmer, Kevin Kalinsky, Claudine Isaacs, Alexandra Thomas, Rebecca Shatsky, Theresa L. Helsten, Andres Forero‐Torres, Minetta C. Liu, Lamorna Brown Swigart, Emmanuel Petricoin, Julia Wulfkuhle, Smita Asare, Amy Wilson, Ruby Singhrao, Laura Sit, Gillian L. Hirst, Scott Berry, Ashish Sanil, Adam L. Asare, Jeffrey B. Matthews, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Douglas Yee, Laura J. van’t Veer, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Laura J. Esserman
Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo<sup>1</sup>H MR Spectroscopy—A Pilot Study at 4 T
Sina Meisamy, Patrick J. Bolan, Eva H. Baker, Robin Bliss, Evin Gulbahce, Lenore I. Everson, Michael T. Nelson, Tim H. Emory, Todd M. Tuttle, Douglas Yee, Michael Garwood